Display Settings:

Format

Send to:

Choose Destination
Am J Psychiatry. 2005 Feb;162(2):377-9.

Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.

Author information

  • Brown Medical School and Butler Hospital, 345 Blackstone Blvd., Providence, RI 02906, USA. Katharine_Phillips@brown.edu

Abstract

OBJECTIVE:

Although body dysmorphic disorder often responds to serotonin reuptake inhibitors (SRIs), most patients do not respond or respond only partially. However, placebo-controlled studies of augmentation of SRIs have not been done. Furthermore, although 40%-50% of patients are delusional, studies of antipsychotic medications have not been done.

METHOD:

Twenty-eight patients with body dysmorphic disorder or its delusional variant participated in an 8-week, placebo-controlled, double-blind, parallel-group study of pimozide augmentation of fluoxetine.

RESULTS:

Pimozide was not more effective than placebo: two (18.2%) of 11 subjects responded to pimozide and three (17.6%) of 17 subjects responded to placebo. There was no significant effect of baseline delusionality on endpoint severity of body dysmorphic disorder. Delusionality did not decrease significantly more with pimozide than placebo.

CONCLUSIONS:

Pimozide augmentation of fluoxetine treatment for body dysmorphic disorder was not more effective than placebo, even in more delusional patients. Further studies of augmentation for SRIs are needed.

PMID:
15677604
[PubMed - indexed for MEDLINE]
PMCID:
PMC1622893
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Write to the Help Desk